Product Pharmacovigilance
Explore all topics, guides, and frameworks related to Product Pharmacovigilance.
Articles in this section
19- Receptor-Directed Monoclonal Antibodies: Receptor Blockade, Modulation and Pharmacovigilance Understand how receptor-directed monoclonal antibodies alter receptor signalling, how representative products illustrate different intervention points, and how receptor biology, exposure and immunogenicity shape pharmacovigilance. Read Article →
- Ligand-Neutralising Monoclonal Antibodies: Mechanism, Clinical Use and Pharmacovigilance Understand how ligand-neutralising monoclonal antibodies modify soluble signalling pathways, why their safety profiles depend on ligand biology and exposure, and how mechanism informs pharmacovigilance without replacing product-specific evidence. Read Article →
- Monoclonal Antibodies: Classification by Mechanism of Action and Pharmacovigilance Understand the principal mechanisms by which therapeutic monoclonal antibodies produce biological effects and how those mechanisms provide a framework for pharmacovigilance. Read Article →
- Immune-Checkpoint Monoclonal Antibodies: T-Cell Reinvigoration, Immune-Related Toxicity and Pharmacovigilance Understand how immune-checkpoint antibodies alter physiological immune brakes, why their safety profile differs from direct cytotoxic antibodies, and how pharmacovigilance should connect immune activation with clinical events. Read Article →
- Cell-Directed Monoclonal Antibodies: Cell Depletion, Fc-Mediated Mechanisms and Pharmacovigilance Understand how cell-directed monoclonal antibodies recognise target cells, how Fc-dependent and other mechanisms produce cell depletion, and how target-cell biology determines pharmacovigilance assessment. Read Article →
- Monoclonal Antibodies: Biology, Development and Pharmacovigilance Understand how therapeutic monoclonal antibodies work as biological medicines and how their molecular design, target biology, development and clinical use determine their pharmacovigilance characteristics. Read Article →
- Monoclonal Antibodies: Scientific Classification and Pharmacovigilance Landscape Understand the therapeutic monoclonal-antibody landscape through a multidimensional classification framework and locate major antibody classes, formats and mechanisms within it. Read Article →
- Biosimilars and Generics: Regulatory and Pharmacovigilance Differences Understand why biosimilars are not regulated as conventional generics, how the scientific basis of their development differs, and how those differences affect pharmacovigilance without creating a separate biosimilar PV system. Read Article →
- Biosimilars and Generic Medicines: Regulatory and Pharmacovigilance Differences Understand the conceptual and regulatory differences between generic medicines and biosimilars, including active-substance identity, bioequivalence, biological comparability, reference-product evidence and the implications for pharmacovigilance. Read Article →
- Biosimilars: Regulatory Concepts, Development and Pharmacovigilance Understand the scientific and regulatory concept of a biosimilar, the stepwise comparability approach used for EU authorisation, the relationship between a biosimilar and its reference biological medicine, and the implications for pharmacovigilance. Read Article →
- Coagulation Factor Products: Classification and Pharmacovigilance Understand how coagulation factor products are classified, how replacement of haemostatic proteins influences efficacy and safety, and how inhibitors, thrombosis, hypersensitivity, traceability and product-specific characteristics shape pharmacovigilance. Read Article →
- Enzyme Replacement Therapies: Classification and Pharmacovigilance Understand how enzyme replacement therapies restore or supplement deficient enzyme activity, how their molecular and delivery characteristics shape safety, and how these characteristics inform pharmacovigilance. Read Article →
- Plasma-Derived Medicinal Products: Classification and Pharmacovigilance Understand how plasma-derived medicinal products are classified, how plasma collection and fractionation shape product characteristics, and how these characteristics influence pharmacovigilance, traceability and safety surveillance. Read Article →
- Recombinant Therapeutic Proteins: Classification and Pharmacovigilance Understand how recombinant therapeutic proteins are classified and developed, how structure and biological function influence their safety, and how these characteristics shape pharmacovigilance across the product lifecycle. Read Article →
- Monoclonal Antibodies: Classification and Pharmacovigilance Understand how therapeutic monoclonal antibodies are structured and classified, how their mechanisms and development characteristics influence safety, and how these properties shape pharmacovigilance across the product lifecycle. Read Article →
- Vaccines: Classification and Pharmacovigilance Understand how vaccines are classified, how vaccine composition and platform influence safety surveillance, and how product-specific pharmacovigilance operates within the wider EU pharmacovigilance system. Read Article →
- Biological Products and Pharmacovigilance: Why Product Characteristics Matter Understand why biological-product pharmacovigilance requires product-specific scientific knowledge, how molecular and manufacturing characteristics influence safety evidence, and how those characteristics connect to product identification, immunogenicity and lifecycle surveillance. Read Article →
- Biological Medicinal Products: Classification, Development and Pharmacovigilance Understand what makes a medicinal product biological, how biological medicinal products are classified in the EU, how major product families relate to one another, and why their biological and manufacturing characteristics create distinctive pharmacovigilance requirements. Read Article →
- The Evolution of Biological Medicines: From Blood Products to Advanced Therapies Trace the major technological and regulatory transitions that shaped biological medicines, and understand how each transition introduced new product characteristics, safety questions and pharmacovigilance requirements. Read Article →